The control of leprosy will be facilitated by the identification of major Mycobacterium leprae-specific antigens which mirror the immune response to the organism across the leprosy spectrum. We have investigated the host response to a 35-kDa protein of M. leprae. Recombinant 35-kDa protein purified from Mycobacterium smegmatis resembled the native antigen in the formation of multimeric complexes and binding by monoclonal antibodies and sera from leprosy patients. These properties were not shared by two forms of 35-kDa protein purified from Escherichia coli. The M. smegmatis-derived 35-kDa protein stimulated a gamma interferon-secreting T-cell proliferative response in the majority of paucibacillary leprosy patients and healthy contacts of leprosy patients tested. Cellular responses to the protein in patients with multibacillary leprosy were weak or absent, consistent with hyporesponsiveness to M. leprae characteristic of this form of the disease. Almost all leprosy patients and contacts recognized the 35-kDa protein by either a T-cell proliferative or an immunoglobulin G antibody response, whereas few tuberculosis patients recognized the antigen. This specificity was confirmed in guinea pigs, with the 35-kDa protein eliciting strong delayed-type hypersensitivity in M. leprae-sensitized animals but not in those sensitized with Mycobacterium tuberculosis or Mycobacterium bovis BCG. Therefore, the M. leprae 35-kDa protein appears to be a major and relatively specific target of the human immune response to M. leprae and is a potential component of a diagnostic test to detect exposure to leprosy or a vaccine to combat the disease.
Leprosy is a chronic intracellular infection affecting predominantly the skin and peripheral nerves. The clinicopathological spectrum of the disease reflects the host immune response to Mycobacterium leprae, the causative agent (4) . At the tuberculoid pole of the spectrum, patients mount a strong cell-mediated immune response against antigens of M. leprae. This is characterized by a strong type 1-like cytokine pattern, resulting in a reduction of the bacterial load in patient tissues (36) . Individuals exposed to leprosy who control the infection show strong cellular reactivity but without immune pathology. At the lepromatous end of the spectrum, patients display disseminated infection, with large numbers of mycobacteria in tissues, high levels of anti-M. leprae antibodies, and weak or absent cellular immunity to M. leprae (4) . Although the introduction of multidrug therapy for the treatment of leprosy has been associated with a reduction in the number of registered patients, an effective leprosy vaccine would complement chemotherapy and help eradicate the disease. Monitoring of the effectiveness of leprosy control will rely on the development of specific diagnostic tests for the early detection of infection with M. leprae, as the currently used lepromin and leprosin skin test reagents lack specificity. Such tests will need to distinguish between exposure to leprosy and other antigenically similar mycobacteria, such as Mycobacterium tuberculosis. Furthermore, candidate antigens should be recognized by cellular or antibody responses across the leprosy spectrum in order to detect all infected individuals. Although a number of M. leprae antigens have been recognized as major targets of the host immune response (15) (16) (17) (18) , all have closely related homologs in M. tuberculosis, making them unlikely candidates as leprosyspecific diagnostic reagents.
The 35-kDa protein of M. leprae was initially identified through the binding of M. leprae-specific monoclonal antibodies (MAbs) (12, 13) . Independently, major membrane protein I of M. leprae was purified by biochemical methods and identified as the same 35-kDa protein (11) . Serological assays based on a MAb inhibition enzyme-linked immunosorbent assay (ELISA) detected antibodies to the 35-kDa protein in almost all lepromatous leprosy patients (25, 31) . The levels of these antibodies correlate strongly with the antigenic load and decline with effective chemotherapy (20, 26) . A crude membrane fraction of M. leprae, containing predominantly the 35-kDa protein, elicited strong T-cell proliferative responses in tuberculoid leprosy patients, suggesting that the protein was also recognized by the human cellular immune response (19) .
Recently, the gene encoding the M. leprae 35-kDa protein has been isolated and characterized (35) . The limited distribution of the protein (13) was confirmed at the genetic level, as the gene is absent from M. tuberculosis and Mycobacterium bovis bacillus Calmette-Guérin (BCG), the current vaccine used against tuberculosis (TB) and leprosy. In order to explore the cellular reactivity of the protein across the leprosy spectrum, we have purified recombinant 35-kDa proteins from mycobacterial and Escherichia coli expression systems and compared the recombinant products. The Mycobacterium smegmatis-derived recombinant 35-kDa protein was recognized by the immune response of over 90% of leprosy patients and healthy leprosy contacts. Moreover, the 35-kDa protein elicited specific delayed-type hypersensitivity (DTH) responses in M. leprae-sensitized animals, highlighting its potential use in leprosy diagnosis and/or vaccination. with an IFN-␥ level of Ͼ10.1 IU/ml, the mean of the control group plus 2 standard deviations (SD), was considered positive.
Antibody binding to the 35-kDa protein. Antibodies to the 35-kDa protein were detected by indirect ELISA. Microtiter plate wells were coated with antigen at a concentration of 10 g/ml overnight at room temperature. The plates were washed and blocked with 3% bovine serum albumin, patient's sera (diluted 1:100) were added, and the plates were incubated for 90 min at 37ЊC. The plates were washed, alkaline phosphatase-conjugated anti-human IgG was added, and the plates were incubated for 60 min at 37ЊC. Binding was visualized by the addition of n-nitrophenyl phosphate (1 mg/ml), and the A 405 was measured. Individuals who had an absorbance of greater than 0.337, which was the mean of 40 endemic control serum samples plus 2 SD, were considered positive. The binding of MAbs and pooled lepromatous leprosy sera to the recombinant 35-kDa proteins was measured by ELISA with protein concentrations of 100 pg/ml to 100 g/ml. Denaturation of the M. smegmatis-derived 35-kDa protein for use in ELISA was performed by heating at 100ЊC for 5 min. 
RESULTS
Characterization of the M. leprae 35-kDa protein purified from M. smegmatis and E. coli. In plasmid pWL19 (35) , the gene encoding the M. leprae 35-kDa protein was placed under the control of the promoter region from the ␤-lactamase gene of a highly amoxicillin-resistant mutant of Mycobacterium fortuitum (33) . This resulted in high-level expression of the gene in M. smegmatis. M. leprae 35-kDa protein was purified by affinity chromatography from the sonicate of recombinant heat-killed M. smegmatis containing pWL19. The preparation contained a single 35-kDa species as assessed by SDS-PAGE (Fig. 1A) . Typical yields of protein ranged from 1 to 2 mg of protein per liter of culture. Immunoblotting for lipoarabinomannan, HSP65, and antigen 85B showed that the protein preparation was free of these major immunogenic mycobacterial components (data not shown). Two forms of E. coli-derived M. leprae 35-kDa protein were also produced, one as an MBP-35-kDa fusion protein and the second as a histidinetagged 35-kDa protein (Fig. 1A) . All three forms of the recombinant protein reacted in an immunoblot with anti-M. leprae 35-kDa protein MAb CS-38 (Fig. 1B) .
Since the native M. leprae 35-kDa protein, purified from the sonicate of M. leprae, exists as a multimer of 955 kDa (35) Fig. 2A) . MAb ML-03, which was generated against MLS, reacts only with the protein in its nondenatured state (8, 13) . This MAb bound only the M. smegmatis, not the E. coli, forms of the protein (Fig. 2B ). Sera from lepromatous leprosy patients reacted exclusively with the M. smegmatis-derived 35-kDa protein (Fig. 2C) . Denaturation of the M. smegmatis recombinant 35-kDa protein by heating abolished the reactivity of MAb ML-03 and the leprosy serum pool but did not affect the binding of MAb CS-38 (data not shown). These data indicate that the recombinant 35-kDa protein purified from M. smegmatis retains conformational determinants present on the native antigen but absent from the E. coli products.
The 35-kDa protein induces strong and specific lymphoproliferative responses. The proliferation of PBMCs from leprosy patients and their healthy contacts and TB patients was tested to determine the magnitude and specificity of the cellular immune response recognized by the M. smegmatis-derived M. leprae 35-kDa protein. None of the groups showed any defect in proliferative responses to M. tuberculosis PPD (Fig. 3A) or the mitogen concanavalin A (data not shown). The majority of contacts and PB leprosy patients showed strong proliferative responses to MLS, with similar proportions of individuals responding to the 35-kDa protein ( Fig. 3B and C) . A total of 26 of 28 individuals in these two groups who mounted a response to MLS were responsive to the 35-kDa protein. Significantly reduced proliferative responses to the 35-kDa protein were observed in MB leprosy patients, consistent with the defective T-lymphocyte proliferative response to M. leprae observed in these patients. A few MB leprosy patients (3 of 13) who failed to respond to MLS did respond to the 35-kDa protein ( Fig. 3B and C). Only 2 of 10 TB patients exhibited positive PBMC proliferation in response to the 35-kDa protein, and both had strong proliferative responses to MLS, indicative of exposure to leprosy (Fig. 3B and C) . No significant responses were seen in the PBMCs of the 10 BCG vaccinees tested, in response to either MLS (mean ⌬cpm Ϯ SD, 1,035 Ϯ 160) or the 35-kDa protein (mean ⌬cpm Ϯ SD, 1,335 Ϯ 271).
IFN-␥ production in response to the 35-kDa protein. IFN-␥ is a key cytokine in the resistance to mycobacterial infection (9, 10) . We examined whether the stimulation of PBMCs by the 35-kDa protein is associated with enhanced production of this cytokine. All four groups produced similar amounts of IFN-␥ in response to M. tuberculosis PPD (Fig. 4A) . The 35-kDa protein induced high levels of IFN-␥ from the PBMCs of healthy leprosy contacts and PB leprosy patients, with 83% of contacts and 72% of PB leprosy patients exhibiting positive responses to the protein (Fig. 4C) . IFN-␥ responses comparable to that elicited by the recombinant 35-kDa protein were produced in response to MLS by these two groups (Fig. 4B and  C) . Lower levels of IFN-␥ were produced by MB leprosy patients in response to the recombinant 35-kDa protein and MLS ( Fig. 4B and C) . As observed in the proliferative responses, some MB patients produced IFN-␥ in response to the 35-kDa protein in the absence of such responsiveness to MLS. PBMCs from the majority of TB patients did not produce appreciable amounts of IFN-␥ upon stimulation with the 35-kDa protein, while most responded to MLS (Fig. 4B and C) .
Responses to the 35-kDa protein correlate with exposure to the leprosy bacillus and not M. tuberculosis. As the patterns of proliferative and IFN-␥ responsiveness to the 35-kDa protein appeared to resemble the corresponding responses to MLS and not PPD of M. tuberculosis, the statistical significance of these responses was compared by using Spearman's rank correlation. There was a strong correlation between proliferative responses to the M. leprae 35-kDa protein and MLS (r s ϭ Although a high proportion of PB leprosy patients and healthy leprosy contacts showed strong T-cell proliferative responses to the 35-kDa protein, this was not reflected in the MB leprosy group, who characteristically have weak T-cell responses and high levels of antibodies to M. leprae antigens (4). The level of antibodies to the purified M. smegmatis-derived M. leprae 35-kDa protein in all subjects was examined by ELISA (Fig. 5 ). MB leprosy patients had the highest levels of IgG antibodies recognizing the 35-kDa protein, although the proportion of seropositive individuals in this group (55%) was lower than previously observed for untreated MB leprosy patients (25) . This was due to the inclusion of patients who either were undergoing or had completed multidrug therapy, as the levels of anti-35-kDa-protein antibodies decline with effective chemotherapy (20, 26) . A smaller proportion of PB leprosy patients (28%) had anti-35-kDa-protein antibodies, and only one individual in each of the leprosy contact and TB groups was seropositive. Serum specimens from 15 TB patients from an area in which leprosy is not endemic were all seronegative for the 35-kDa protein (data not shown).
When both T-cell proliferative and antibody responses to the 35-kDa protein were considered, over 90% of leprosy patients and contacts recognized this protein (Fig. 6) . By contrast, only 2 of 10 TB patients responded to the protein. Most individuals mounted exclusively either a T-cell proliferative response or an antibody response to the 35-kDa protein, not both. No overlap in responses was observed in the MB and contact groups, and only a small degree of overlap occurred in the PB (2 of 14) and TB (1 of 10) groups. This apparent dichotomy in the response to the 35-kDa protein was not exhibited in response to M. leprae itself, since a number of patients exhibited both proliferative and antibody responses to MLS (data not shown).
The M. leprae 35-kDa protein elicits specific DTH. The suitability of the M. leprae 35-kDa protein as a skin test reagent for the detection of leprosy exposure was assessed. The M. smegmatis recombinant 35-kDa protein elicited strong DTH in all M. leprae-sensitized animals, similar to the response elicited by MLS (Table 1) . When guinea pigs were sensitized with M. tuberculosis, the 35-kDa protein elicited weak DTH in only one of eight animals. A similar result was obtained with animals sensitized with the vaccine strain BCG. By contrast, MLS lacked this specificity, eliciting DTH in all M. tuberculosis-and BCG-sensitized animals.
DISCUSSION
As an effective T-lymphocyte response is essential for protection against mycobacterial infection, the identification of antigens involved in such responses is of prime importance. This study indicates that the M. leprae 35-kDa protein is one such antigen. Almost all subjects (26 of 28) who demonstrated a cellular response to M. leprae showed a T-cell proliferative response to the 35-kDa protein with the release of IFN-␥. Immune responses to the antigen parallel those to M. leprae across the leprosy spectrum, with cellular immune responses dominant in PB leprosy patients and healthy subjects exposed to leprosy and antibody responses maximal in MB leprosy patients (Fig. 6) . The previously documented discrimination between leprosy and TB patients in antibody responses to the protein (23, 32) was evident in cellular reactivity to the antigen. The small proportion of TB patients with proliferative responses to the 35-kDa protein also demonstrated strong responses to MLS, suggesting that the reactivity of these patients in an area in which leprosy is endemic may have been due to their exposure to leprosy. This is consistent with the observation that proliferative and IFN-␥ responses to the 35-kDa protein were more strongly correlated with responses to MLS than to M. tuberculosis PPD.
Although many of the MB leprosy patients showed no response to the 35-kDa protein, consistent with their specific unresponsiveness to M. leprae, a proportion (3 of 13) who failed to respond to M. leprae did respond to the protein. It was not considered that the reactivity was due to contamination of the 35-kDa protein with other M. smegmatis antigens, as other proteins were not apparent upon SDS-PAGE fractionation (Fig. 1A) and immunoblots for three other major mycobacterial antigens were negative. Furthermore, TB patients who were PPD positive but unresponsive to the 35-kDa protein would have recognized any cross-reactive M. smegmatis contaminating proteins if present. Previous reports have described a level of T-cell reactivity to single M. leprae antigens in M. leprae-unresponsive MB leprosy patients (21, 22, 30) . This has been attributed to the presence of suppressive components in unfractionated M. leprae preparations, but not recombinant proteins, which inhibit T-cell responses to the whole organism. This possible explanation for lepromatous unresponsiveness is different from that proposed by Kaleab et al. (14) , who suggested that the reactivity of MB leprosy patients to M. tuberculosis PPD is due to recognition of specific determinants on M. tuberculosis proteins.
The inverse relationship between cell-mediated and IgG antibody responses to the 35-kDa protein is a striking example of the immune deviation present in leprosy. On the basis of our FIG. 5 . Antibody levels to the 35-kDa protein in sera of leprosy and TB patients and healthy leprosy contacts. Sera from all subjects were diluted 1/100, and the levels of anti-35-kDa-protein IgG antibodies were determined by ELISA. A level greater than the mean plus 2 SD of control subjects (A 405 Ͼ 0.337) was considered positive. (3), genetic contribution from the host (2), and the cytokine milieu at the site of T-cell activation (29, 36) . Determining the relative importance of these mechanisms will require the availability of M. leprae antigens, such as the 35-kDa protein, which mirror the response to the whole organism. The utility of recombinant mycobacterial antigens may be enhanced if the recombinant form more closely resembles the native protein. Our approach was to purify recombinant protein from the rapidly growing, nonpathogenic M. smegmatis. The 35-kDa protein of M. leprae purified from this mycobacterial host folded into the correct conformation, as assessed by its recognition by conformation-dependent MAbs (Fig. 2) and its formation of multimeric complexes. By contrast, the recombinant 35-kDa protein appeared to be incorrectly folded in E. coli. The M. smegmatis form of the protein was preferentially bound by sera from leprosy patients, indicating that nonlinear determinants were dominant in the human antibody response to this antigen. The lack of recognition of denatured M. smegmatis recombinant 35-kDa protein suggested that the inability of the E. coli recombinant 35-kDa protein to bind leprosy sera was most likely due to differences in the conformation of the proteins, rather than posttranslational modification. Previous studies have also shown enhanced recognition of mycobacterium-derived proteins by the cellular immune response. For example, the MPT64 protein of M. tuberculosis when purified from M. smegmatis was more potent in eliciting DTH than the E. coli recombinant MPT64 and preferentially stimulated lymphocytes from M. tuberculosis-infected individuals to secrete IFN-␥ (28). The M. smegmatis-derived recombinant 35-kDa protein elicited strong and specific DTH in M. leprae-sensitized guinea pigs (Table 1) . Although the basis for the enhanced immunogenicity of recombinant proteins purified from mycobacteria in DTH and T-cell assays is unclear, presentation of the protein in the correct conformation may lead to moreefficient antigen processing and T-cell activation.
Monitoring of the effectiveness of leprosy control programs is hindered by the lack of specific and sensitive diagnostic reagents with which to detect subclinical infection with M. leprae and measure transmission within a community. For a single mycobacterial protein to be useful as a diagnostic reagent, it should be limited in distribution, must be widely recognized by the desired population, and must stimulate the correct pattern of immune responses. The M. leprae 35-kDa protein fulfills all these criteria; it is absent from M. tuberculosis and M. bovis BCG, over 90% of leprosy patients and leprosy contacts respond to the protein, and it stimulates IFN-␥ production and DTH. Only a few mycobacterial proteins have been evaluated for each of these criteria. For example, the M. leprae 10-kDa, or GroES, protein elicited DTH in M. lepraesensitized guinea pigs and is widely recognized by leprosy patients but lacks specificity, as it shares 90% identity with its M. tuberculosis counterpart (18) . The immunodominant M. bovis BCG 70-kDa heat shock protein elicits DTH in tuberculinpositive subjects (5), but the dominant T-cell epitopes are shared with the M. leprae homolog (1) . Similarly, the 85B antigen of M. tuberculosis also elicits DTH, but the protein is common to all mycobacteria (34) . Our finding that the 35-kDa protein elicits no or only weak DTH in M. tuberculosis-or BCG-sensitized animals further highlights the potential use of this protein as a component of a diagnostic test for leprosy exposure.
In addition, the M. leprae 35-kDa protein is a strong candidate as a component of an M. leprae vaccine. As the current vaccine strain BCG lacks the antigen, the introduction of this protein to extend the antigenic repertoire of BCG may enhance the protective efficacy of BCG vaccination against leprosy infection. We are currently evaluating the immunogenicity of BCG overexpressing the gene encoding the M. leprae 35-kDa protein, with a view to developing a more effective recombinant vaccine for immunoprophylaxis against leprosy. 
